Discovery of New Tuberculosis Drug Leads Targeting Cell Wall Biosynthesis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1082533

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

There is a desperate need for the development of new therapies for the treatment of TB due to widespread resistance of Mycobacterium tuberculosis, the causative agent of TB, to current therapies. The overall goal of this research project is to identify new TB drug leads through the development of structural analogues of bacterially-derived natural products called the sansanmycins that inhibit cell wall synthesis in Mycobacterium tuberculosis.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $714,816.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Molecular Medicine

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug discovery | enzyme inhibition | mycobacteria | mycobacterial infection | tuberculosis

Related Links